Back to Journals » Neurobehavioral HIV Medicine » Volume 2

Depression care and prevalence in HIV-positive individuals

Authors Raymond L Ownby, Robin J Jacobs, Drenna Waldrop-Valverde, et al.

Published 30 August 2010 Volume 2010:2 Pages 73—83

DOI https://doi.org/10.2147/NBHIV.S7296

Review by Single-blind

Peer reviewer comments 4

Raymond L Ownby1, Robin J Jacobs1, Drenna Waldrop-Valverde2, Felicia Gould2

1Department of Psychiatry and Behavioral Medicine, Nova Southeastern University, Fort Lauderdale, Florida, USA; 2Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, Florida, USA

Abstract: Depression is among the most common neuropsychiatric disturbances seen in ­individuals with HIV infection. Associated with sad mood, disturbed sleep and appetite, and low energy, the symptoms of depression may be difficult to distinguish from those of the ­infection itself. Depression has enormous clinical significance in this group of patients, not only for the misery and poor quality of life it causes but also for its negative effect on patients’ sexual risk behavior, substance use, and medication adherence. Depression has been ­associated with patients’ immune system functioning and with poorer disease outcomes. Although it can be effectively treated in most individuals, fewer than one half of patients with depression are ­correctly diagnosed and still fewer receive adequate treatment. Effective treatments for ­depression in this group include antidepressant medication, individual and group psychotherapy, and social support interventions. Given the significance of this common yet under-recognized problem, clinicians should be aware of the implications of failing to aggressively treat depression in HIV-infected individuals.

Keywords: HIV, depression, SSRI, cognitive-behavioral therapy, neuroinflammation, stigma

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other articles by this author:

Readers of this article also read:

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

Acquired hemophilia A: emerging treatment options

Janbain M, Leissinger CA, Kruse-Jarres R

Journal of Blood Medicine 2015, 6:143-150

Published Date: 8 May 2015

Profile of efraloctocog alfa and its potential in the treatment of hemophilia A

George LA, Camire RM

Journal of Blood Medicine 2015, 6:131-141

Published Date: 24 April 2015

A new recombinant factor VIII: from genetics to clinical use

Santagostino E

Drug Design, Development and Therapy 2014, 8:2507-2515

Published Date: 12 December 2014

Second case report of successful electroconvulsive therapy for a patient with schizophrenia and severe hemophilia A

Saito N, Shioda K, Nisijima K, Kobayashi T, Kato S

Neuropsychiatric Disease and Treatment 2014, 10:865-867

Published Date: 16 May 2014

Rituximab for managing acquired hemophilia A in a case of chronic neutrophilic leukemia with the JAK2 kinase V617F mutation

Imashuku S, Kudo N, Kubo K, Saigo K, Okuno N, Tohyama K

Journal of Blood Medicine 2012, 3:157-161

Published Date: 5 December 2012

The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia

Rivka Yatuv, Micah Robinson, Inbal Dayan-Tarshish, et al

International Journal of Nanomedicine 2010, 5:581-591

Published Date: 6 August 2010